Positionspapier: Empfehlungen zur Behandlung der chronischen Rhinosinusitis während der COVID-19-Pandemie im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC) – Diese Empfehlungen basieren auf dem EAACI Positionspapier „Treatment of chronic RhinoSinusitis with nasal polyps (CRSwNP) in the COVID-19 pandemics – An EAACI Position Paper”, Allergy, 2020 und wurden auf die Situation im deutschen Gesundheitswesen angepasst

 

 Permissions and Reprints

Zusammenfassung

Hintergrund Von der chronischen Rhinosinusitis (CRS) sind weltweit etwa 5–12 % der Allgemeinbevölkerung betroffen. Die CRS gilt als chronische Atemwegserkrankung, die nach den Empfehlungen der WHO ein Risikofaktor für COVID-19-Patienten sein kann. Die entzündlichen Veränderungen der Nasenschleimhäute bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) sind in den meisten Fällen vom Entzündungsendotyp 2 (T2).

Methoden Der aktuelle Wissensstand sowohl zu COVID-19 als auch zu den Behandlungsmöglichkeiten von CRSwNP wurde durch eine Literaturrecherche in Medline, Pubmed, internationalen Leitlinien, der Cochrane Library und im Internet analysiert.

Ergebnisse Auf Grundlage der internationalen Literatur, der aktuellen Empfehlungen der WHO und anderer internationaler Organisationen sowie der bisherigen Erfahrungen gab ein Expertengremium von EAACI und ARIA Empfehlungen für die Behandlung von CRSwNP während der COVID-19-Pandemien.

Schlussfolgerung Intranasale Kortikosteroide stellen die Standardbehandlung für CRS bei Patienten mit einer SARS-CoV-2-Infektion dar. Chirurgische Behandlungen sollten auf ein Minimum reduziert werden und nur bei Patienten mit lokalen Komplikationen und solchen, für die keine anderen Behandlungsmöglichkeiten bestehen, durchgeführt werden. Systemische Kortikosteroide sollten bei COVID-19-Patienten vermieden werden. Die Behandlung mit Biologika kann bei nicht infizierten Patienten unter sorgfältiger Überwachung fortgesetzt werden und sollte während einer SARS-CoV-2-Infektion vorübergehend unterbrochen werden.

Publication History

Article published online:
08 May 2020

© Georg Thieme Verlag KG
Stuttgart · New York

• Literatur

• 1 Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome?. Rhinology 2020 58.
  PubMedGoogle Scholar
• 2 Iacobucci G. Sixty seconds on... anosmia. BMJ 2020; 368: m1202
  PubMedGoogle Scholar
• 3 Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
  CrossrefPubMedGoogle Scholar
• 4 WHO. Coronavirus disease (COVID-19 pandemic). 2020 01.04.2020; Available from: https://www.who.int/
  PubMedGoogle Scholar
• 5 Luers JC, Klussmann JP, Guntinas-Lichius O. The Covid-19 pandemic and otolaryngology: What it comes down to?. Laryngo-Rhino-Otol 2020; DOI: 10.1055/a-1095-2344.
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 ECDC. Situation update worldwide. 2020 07.04.2020; Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases
  PubMedGoogle Scholar
• 7 Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020; 92 (04) 418-423
  CrossrefPubMedGoogle Scholar
• 8 Zhang JJ. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 1-12 DOI: https://doi.org/10.1111/all.14238.
  CrossrefPubMedGoogle Scholar
• 9 Zhou F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
  CrossrefPubMedGoogle Scholar
• 10 Dreher M, Bickenbach KA, Balfanz P. et al. The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. Dtsch Arztebl Int 2020; 271-278
  PubMedGoogle Scholar
• 11 Hastan D. et al. Chronic rhinosinusitis in Europe – an underestimated disease. A GALEN study. Allergy 2011; 66 (09) 1216-1223
  CrossrefPubMedGoogle Scholar
• 12 Hirsch AG. et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy 2017; 72 (02) 274-281
  CrossrefPubMedGoogle Scholar
• 13 Ostovar A. et al. Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology 2018; 57 (01) 43-48
  PubMedGoogle Scholar
• 14 Shi JB. et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy 2015; 70 (05) 533-539
  CrossrefPubMedGoogle Scholar
• 15 Vaira LA. et al. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope 2020; 1 DOI: https://doi.org/10.1002/lary.28692.
  CrossrefPubMedGoogle Scholar
• 16 Dietz de Loos D. et al. Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. J Allergy Clin Immunol 2019; 143 (03) 1207-1214
  CrossrefPubMedGoogle Scholar
• 17 Fokkens WJ. et al European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012; 23: 3 ; preceding table of contents 1–298
  PubMedGoogle Scholar
• 18 Rosenfeld RM. Clinical practice guideline adult sinusitis. Otolaryngology – Head and Neck Surgery. Orlando, FL: Elsevier 2007; 137 (Suppl. 03) S1-S31 https://doi.org/10.1016/j.otohns.2007.06.726
  PubMedGoogle Scholar
• 19 Fokkens WJ. EPOS2020: a major step forward. Rhinology 2020; 58 (01) 1
  CrossrefPubMedGoogle Scholar
• 20 Fokkens WJ. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58 (Suppl. 29) 1-464
  CrossrefPubMedGoogle Scholar
• 21 Soyka MB. et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4. J Allergy Clin Immunol 2012; 130 (05) 1087-1096.e10
  CrossrefPubMedGoogle Scholar
• 22 Klimek L. et al. Immunologie der Polyposis nasi als Grundlage für eine Therapie mit Biologicals. Hno 2018; 67 (01) 15-26
  PubMedGoogle Scholar
• 23 Tomassen P. et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. The Journal of allergy and clinical immunology 2016; 137 (05) 1449-1456.e4
  CrossrefPubMedGoogle Scholar
• 24 Koennecke M. et al. Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo journal international 2018; 27 (02) 56-65
  CrossrefPubMedGoogle Scholar
• 25 Tsetsos N. et al. Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology 2018; 56 (01) 11-21
  PubMedGoogle Scholar
• 26 Hellings PW. et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy 2017; 72 (09) 1297-1305
  CrossrefPubMedGoogle Scholar
• 27 Fokkens WJ. Evidence-based and precision medicine two of a kind. Rhinology 2017; 55 (01) 1-2
  PubMedGoogle Scholar
• 28 Hox V. et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical and translational allergy 2020; 10: 1
  CrossrefPubMedGoogle Scholar
• 29 Fokkens WJ. et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50 (01) 1-12
  PubMedGoogle Scholar
• 30 Liao B. et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy 2018; 73 (07) 1459-1469
  CrossrefPubMedGoogle Scholar
• 31 Philpott CM. et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respiratory research 2018; 19 (01) 129
  CrossrefPubMedGoogle Scholar
• 32 Wu D. et al. Clinical Phenotypes of Nasal Polyps and Comorbid Asthma Based on Cluster Analysis of Disease History. J Allergy Clin Immunol Pract 2018; 6 (04) 1297-1305.e1
  CrossrefPubMedGoogle Scholar
• 33 Khan A. et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2018; 57 (01) 32-42
  CrossrefPubMedGoogle Scholar
• 34 Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. Journal of asthma and allergy 2016; 9: 45-53
  PubMedGoogle Scholar
• 35 Lin DC. et al. Association between severity of asthma and degree of chronic rhinosinusitis. American journal of rhinology & allergy 2011; 25 (04) 205-208
  CrossrefPubMedGoogle Scholar
• 36 Shaw DE. et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. The European respiratory journal 2015; 46 (05) 1308-1321
  CrossrefPubMedGoogle Scholar
• 37 De Greve G. et al. Endotype-driven treatment in chronic upper airway diseases. Clinical and translational allergy 2017; 7: 22
  CrossrefPubMedGoogle Scholar
• 38 Seys SF. et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respiratory research 2017; 18 (01) 39
  CrossrefPubMedGoogle Scholar
• 39 Zhang Y. et al. Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps. Allergy 2018; 74 (01) 131-140
  PubMedGoogle Scholar
• 40 Green RH. et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57 (10) 875-879
  CrossrefPubMedGoogle Scholar
• 41 GINA, Global Strategy for Asthma Management and Prevention (2019 update). 2019 www.ginasthma.org
  PubMedGoogle Scholar
• 42 Orlandi RR. et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. International forum of allergy & rhinology 2016; 6 (Suppl. 01) S22-S209
  PubMedGoogle Scholar
• 43 Rondón C. et al. Clinical Management and Use of Health Care Resources in the Treatment of Nasal Polyposis in Spanish Allergy Centers: The POLAR Study. Journal of investigational allergology & clinical immunology 2015; 25 (04) 276-282
  PubMedGoogle Scholar
• 44 Wei CC, Adappa ND, Cohen NA. Use of topical nasal therapies in the management of chronic rhinosinusitis. The Laryngoscope 2013; 123 (10) 2347-2359
  PubMedGoogle Scholar
• 45 Stuck BA. et al. Guideline for “rhinosinusitis”-long version: S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery. HNO 2018; 66 (01) 38-74
  CrossrefPubMedGoogle Scholar
• 46 Chong LY. et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. The Cochrane database of systematic reviews 2016; 4: CD011996
  PubMedGoogle Scholar
• 47 Klimek L, Bachert C. Current aspects of nasal glucocorticosteroid therapy. HNO 2000; 48 (07) 544-555
  CrossrefPubMedGoogle Scholar
• 48 Rudmik L, Soler ZM. Medical Therapies for Adult Chronic Sinusitis: A Systematic Review. Jama 2015; 314 (09) 926-939
  CrossrefPubMedGoogle Scholar
• 49 Pundir V. et al. Role of corticosteroids in Functional Endoscopic Sinus Surgery--a systematic review and meta-analysis. Rhinology 2016; 54 (01) 3-19
  PubMedGoogle Scholar
• 50 Voorham J. et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy 2018; 74 (02) 273-283
  PubMedGoogle Scholar
• 51 Head K. et al. Short-course oral steroids alone for chronic rhinosinusitis. The Cochrane database of systematic reviews 2016; 4: CD011991
  PubMedGoogle Scholar
• 52 Head K. et al. Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis. The Cochrane database of systematic reviews 2016; 4: CD011992
  PubMedGoogle Scholar
• 53 Price DB. et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy 2018; 11: 193-204
  CrossrefPubMedGoogle Scholar
• 54 Arabi YM. et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 2018; 197 (06) 757-767
  CrossrefPubMedGoogle Scholar
• 55 WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected. 2020 07.04.2020; Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
  PubMedGoogle Scholar
• 56 Kirsche H, Klimek L. ASS-Intoleranz-Syndrom und persistierende Rhinosinusitis: Differentialdiagnostik und Therapie. Hno 2015; 63 (05) 357-363
  CrossrefPubMedGoogle Scholar
• 57 Klimek L, Pfaar O. Aspirin intolerance: does desensitization alter the course of the disease?. Immunology and allergy clinics of North America 2009; 29 (04) 669-675
  CrossrefPubMedGoogle Scholar
• 58 Kowalski ML. et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy 2018; 74 (01) 28-39
  PubMedGoogle Scholar
• 59 Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert review of clinical immunology 2017; 13 (05) 425-437
  CrossrefPubMedGoogle Scholar
• 60 Sanofi-Aventis_Deutschland_GmbH, Dupixent^® 300 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH – Fachinformation. Rote Liste Service GmbH Frankfurt 2020; 21
  PubMedGoogle Scholar
• 61 Fokkens WJ. et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019; 74 (12) 2312-2319
  CrossrefPubMedGoogle Scholar
• 62 Hopkins C. et al. Prevention of chronic rhinosinusitis. Rhinology 2018; 56 (04) 307-315
  PubMedGoogle Scholar
• 63 Kilty SJ. et al. Case-control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps. Rhinology 2018; 56 (02) 155-157
  PubMedGoogle Scholar
• 64 Rudmik L. et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology 2016; 54 (02) 117-128
  PubMedGoogle Scholar
• 65 Bousquet AC, Jutel M, Bachert C. et al Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy 2020. In press
  PubMedGoogle Scholar
• 66 Hayward G. et al Corticosteroids for the common cold. Cochrane Database Syst Rev 2015 Oct; CD008116
  PubMedGoogle Scholar
• 67 Keith PK. et al. Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study. Prim Care Respir J 2012; 21 (03) 267-275
  CrossrefPubMedGoogle Scholar
• 68 Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005; 116 (06) 1289-1295
  CrossrefPubMedGoogle Scholar
• 69 Puhakka T. et al. The common cold: effects of intranasal fluticasone propionate treatment. J Allergy Clin Immunol 1998; 101 (06) 726-731
  CrossrefPubMedGoogle Scholar
• 70 Klimek L. et al. Stellungnahme zur Anwendung von Glukokortikosteroiden bei entzündlichen Erkrankungen der oberen Atemwege. Laryngo-Rhino-Otol 2020; DOI: 10.1055/a-1148-3553.
  Article in Thieme ConnectPubMedGoogle Scholar
• 71 Li X, Xu S, Yu M. et al. Risk factors for severity and mortalityin adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology 2020; DOI: https://doi.org/10.1016/j.jaci.2020.04.006.
  CrossrefPubMedGoogle Scholar
• 72 Papadopoulos NG. et al. Viruses and bacteria in acute asthma exacerbations – a GA(2) LEN-DARE systematic review. Allergy 2011; 66 (04) 458-468
  CrossrefPubMedGoogle Scholar
• 73 Darveaux JI, Lemanske RF. Infection-related asthma. J Allergy Clin Immunol Prac 2014; 2 (06) 658-663
  PubMedGoogle Scholar
• 74 Hewitt R. et al. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis 2016; 10 (02) 158-174
  CrossrefPubMedGoogle Scholar
• 75 DGP: Michael Pfeifer, M.L., Stephanie Korn, Christian Taube, Johann Christian Virchow, Roland Buhl; GPP: Matthias Kopp. STELLUNGNAHME – Asthma-Patienten und COVID-19: Lungenexperten raten: Therapie mit inhalierbaren Steroiden (ICS) unverändert fortführen. 2020 https://pneumologie.de/fileadmin/user_upload/Aktuelles/2020-03-16_Statement_Asthma_und_COVID-19_F.pdf last access date 28.04.2020
  PubMedGoogle Scholar
• 76 Liu F, Xu A, Zhang Y. et al Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and theincrease of eosinophil may predict the outcome of COVID-19 progression. International Journal of Infectious Diseases 2020; DOI: https://doi.org/10.1016/j.ijid.2020.03.013.
  CrossrefPubMedGoogle Scholar
• 77 Gleich GJ. et al. The consequences of not having eosinophils. Allergy 2013; 68 (07) 829-835
  CrossrefPubMedGoogle Scholar
• 78 Abidi K. et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Critical care (London, England) 2008; 12 (02) R59
  CrossrefPubMedGoogle Scholar
• 79 Kulaylat AS. et al. Development and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With Peripheral Eosinopenia on Admission for Clostridium difficile Infection. JAMA surgery 2018; 153 (12) 1127-1133
  CrossrefPubMedGoogle Scholar
• 80 Pouliquen IJ. et al. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. International journal of clinical pharmacology and therapeutics 2015; 53 (12) 1015-1027
  CrossrefPubMedGoogle Scholar
• 81 Ghazi A, Trikha A, Calhoun WJ. Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma. Expert opinion on biological therapy 2012; 12 (01) 113-118
  CrossrefPubMedGoogle Scholar
• 82 Agache I, Beltran J, Akdis C. et al Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. Allergy 2020; 1-20 DOI: https://doi.org/10.1111/all.14221.
  CrossrefPubMedGoogle Scholar
• 83 Howarth P. et al Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J ALLERGY CLIN IMMUNOL 2020; Available from: https://www.jacionline.org/action/showPdf?pii=S0091-6749%2820%2930194-9
  PubMedGoogle Scholar
• 84 Dupilumab Core Company Data Sheet 2019.
  PubMedGoogle Scholar
• 85 CHMP, E.M.A.-. Assessment report – Dupixent 2017 01.04.2020.
  PubMedGoogle Scholar
• 86 Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 2015; 16 (01) 45-56
  CrossrefPubMedGoogle Scholar
• 87 Van Gerven L, Cox PWHT, Fokkens W. et al. Personal protection and delivery of rhinologic and endoscopic skull base procedures during the COVID-19 outbreak. Rhinology – Open access 2020; 58 DOI: https://doi.org/10.4193/Rhin20.119.
  CrossrefPubMedGoogle Scholar
• 88 Lindemann J, Böhm F, Hoffmann T. Chirurgische Aspekte zur Tracheostomie bei Covid-19 positiven Patienten; Stellungnahme im Auftrag der Deutschen Gesellschaft für HNO-Heilkunde, Kopf und Halschirurgie (DGHNO-KHC) und der AG Laryngologie & Trachealerkrankungen. Laryngo-Rhino-Otol 2020; DOI: 10.1055/a-1151-7932.
  Article in Thieme ConnectPubMedGoogle Scholar
• 89 Workman AD. et al. Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. Int Forum Allergy Rhinol 2020; DOI: https://doi.org/10.1002/alr.22577.
  CrossrefPubMedGoogle Scholar
• 90 Rothe C. et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. The New England journal of medicine 2020; 382 (10) 970-971
  CrossrefPubMedGoogle Scholar
• 91 CDC.gov. Center for Disease Control and Prevention. 2020 01.04.2020; Available from: https://www.cdc.gov/
  PubMedGoogle Scholar
• 92 Zou L. et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 2020; 382 (12) 1177-1179
  CrossrefPubMedGoogle Scholar
• 93 Tran K. et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One 2012; 7 (04) e35797
  CrossrefPubMedGoogle Scholar